The Department of Nephrology and Hypertension within Cleveland Clinic’s Glickman Urological & Kidney Institute has a rich history of innovation and research in hypertension. The Department’s Center for Blood Pressure Disorders provides expertise in hypertension management , and is staffed by American Society of Hypertension (ASH) certified hypertension specialists, with a dedicated hypertension lab with space and equipment dedicated to hypertension evaluation and testing. The Department has been designated as a Comprehensive Hypertension Center by the American Society Hypertension, which recognizes expertise in treating patients who have complex or difficult-to-treat hypertension and its co-morbidities.
Besides the standardized use of automated blood pressure devices in our outpatient clinics, we have a large cohort of patients who undergo 24-hour ambulatory blood pressure measurements to help with diagnosis of white coat hypertension, masked hypertension, labile hypertension, and assessment of nocturnal dipping and efficacy of therapy. We also use non-invasive hemodynamic testing to help guide treatment decisions and tailor therapy by assessing neuro-humoral profiles and hemodynamic parameters in our hypertension lab. Central blood pressures have been shown to correlate more strongly with vascular disease than routine peripheral blood pressure measurements, and we have the ability to assess central blood pressure parameters, , including pulse wave analysis and pulse wave velocity. We also have the capability to study endothelial function non-invasively, which could help early detection of endothelial dysfunction for assessment of cardiovascular risk.
The Center has expertise in the field of secondary hypertension management, specifically related to the diagnosis and management of primary hyperaldosteronism, pheochromocytoma, and renal artery stenosis.
The Center follows a collaborative approach to diagnosis, care and monitoring of blood pressure disorders. We work closely with internists, cardiologists, endocrinologists, and vascular medicine specialists to develop a diagnostic and management plan that is tailored to the individual patient. An effective treatment program requires partnership between the patient and care providers. Our Center supports patients with information regarding blood pressure monitoring guidelines, lifestyle changes and nutrition.
Symplicity HTN-3 renal denervation trial
Hyperactivation of the sympathetic nervous system has a major role in the initiation, development and maintenance of hypertension. In prior studies, patients undergoing selective renal denervation to attenuate sympathetic tone have been reported to have significant blood pressure reduction which is sustained over at least a two-year period. The Departments of Nephrology and Hypertension and Cardiology at Cleveland Clinic are participating in the SYMPLICITY HTN-3 trial, which is the first trial in US examining this novel therapy.
The Department of Nephrology and Hypertension is involved in the NIH SPRINT (Systolic Blood Pressure Intervention Trial) to determine whether or not treating systolic blood pressure aggressively will reduce the rate of heart disease and stroke, memory decline or worsening of kidney disease in adults over the age of 55 who already have high blood pressure, with participants followed long-term up to 7 years.
For an appointment, please call 216.444.6771.